Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New muscarinic antagonists from Schering-Plough

Oct. 11, 1996

Copaxone approvable for MS

Oct. 11, 1996

FDA approval for Taro generic drug

Oct. 11, 1996

First launch for olanzapine

Oct. 11, 1996

Potential antipsychotic agents disclosed by Pharmacia & Upjohn

Oct. 11, 1996

Dopamine D3 ligands from Pharmacia & Upjohn

Oct. 11, 1996

New dopamine receptor ligands reported by Neurogen

Oct. 11, 1996

Suntory reports agents for CNS and cerebrovascular disorders

Oct. 11, 1996

Hypnotic agent in the Fujisawa pipeline

Oct. 11, 1996

U.S. approval for anesthetic/analgesic agent

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...